COVID-19 Vaccine Developers Search for Antibodies That ‘First Do No Harm’
An article in Scientific American describing how biotechs and pharma are trying to protect patients without triggering immune system havoc
Consensus summary report for CEPI/BC March 12–13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines
A major challenge during rapid development of COVID-19 vaccines is to avoid safety issues both by thoughtful vaccine design and by thorough evaluation in a timely manner. This report summarizes the evidence presented and provides considerations for safety assessment of COVID-19 vaccine candidates in accelerated vaccine development.